The stock of GE HealthCare Technologies Inc (NASDAQ:GEHC) last traded at $67.71, down -0.62% from the previous session.
Data from the available sources indicates that GE HealthCare Technologies Inc (NASDAQ:GEHC) is covered by 14 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $97.00 and a low of $66.00, we find $84.00. Given the previous closing price of $68.13, this indicates a potential upside of 23.29 percent. GEHC stock price is now -0.52% away from the 50-day moving average and -9.16% away from the 200-day moving average. The market capitalization of the company currently stands at $30.82B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
In total, 4 analysts have assigned it a hold rating, and 9 have given it a buy rating. Brokers who have rated the stock have averaged $83.14 as their price target over the next twelve months.
With the price target reduced from $86 to $66, UBS Downgraded its rating from Neutral to Sell for GE HealthCare Technologies Inc (NASDAQ: GEHC).
In other news, O’Neill Kevin Michael, CEO, PDx sold 15,609 shares of the company’s stock on Jul 31. The stock was sold for $1,206,949 at an average price of $77.32. Upon completion of the transaction, the CEO, PDx now directly owns 24,025 shares in the company, valued at $1.63 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 08, CEO, Ultrasound Rott Roland sold 2,473 shares of the business’s stock. A total of $191,336 was realized by selling the stock at an average price of $77.37. This leaves the insider owning 22,335 shares of the company worth $1.51 million. Insiders disposed of 392,460,263 shares of company stock worth roughly $26.57 billion over the past 1 year. A total of 13.80% of the company’s stock is owned by insiders.
With an opening price of $68.30 on Wednesday morning, GE HealthCare Technologies Inc (NASDAQ: GEHC) set off the trading day. During the past 12 months, GE HealthCare Technologies Inc has had a low of $53.00 and a high of $87.83. As of last week, the company has a debt-to-equity ratio of 1.44, a current ratio of 1.20, and a quick ratio of 0.92. The fifty day moving average price for GEHC is $68.07 and a two-hundred day moving average price translates $74.54 for the stock.
The latest earnings results from GE HealthCare Technologies Inc (NASDAQ: GEHC) was released for Sep, 2023. The company reported revenue of $4.82 billion for the quarter, compared to $4.58 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.38 percent. For the current quarter, analysts expect GEHC to generate $5.09B in revenue.
GE HealthCare Technologies Inc(GEHC) Company Profile
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women’s health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
